scholarly article | Q13442814 |
P50 | author | Frank Struyf | Q55186651 |
P2093 | author name string | Gary Dubin | |
Lan Lin | |||
Jacob Lalezari | |||
Rhoda S Sperling | |||
Mark H Einstein | |||
Archana Chatterjee | |||
HPV-010 Study Group | |||
Marie-Pierre David | |||
Mark M Blatter | |||
Nahida Chakhtoura | |||
Peter Takacs | |||
P2860 | cites work | Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years | Q28255234 |
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory | Q34104222 | ||
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 | ||
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls | Q34708325 | ||
Hepatitis A booster vaccination: is there a need? | Q35548831 | ||
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study | Q35886612 | ||
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years | Q35918834 | ||
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 | ||
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile | Q37860337 | ||
Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial | Q42268011 | ||
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses | Q43782984 | ||
Current status of HBV vaccine escape variants--a mathematical model of their epidemiology | Q45103432 | ||
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine | Q45404942 | ||
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc | Q51865830 | ||
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up | Q83428460 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | vaccine | Q134808 |
phase III clinical trial | Q42824827 | ||
P304 | page(s) | 3435-3445 | |
P577 | publication date | 2014-01-01 | |
P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
P1476 | title | Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial | |
P478 | volume | 10 |